Becton, Dickinson and Co (BDX, Financial) files its latest 10-K with SEC for the fiscal year ended on September 30, 2018. Becton, Dickinson and Co is a healthcare company. It manufacture and sales medical supplies, devices, laboratory equipment and diagnostic products. It operates in two segments BD Medical and BD Life Sciences. Becton, Dickinson and Co has a market cap of $64.76 billion; its shares were traded at around $242.04 with a P/E ratio of 550.09 and P/S ratio of 4.15. The dividend yield of Becton, Dickinson and Co stocks is 1.22%. Becton, Dickinson and Co had annual average EBITDA growth of 4.60% over the past ten years. GuruFocus rated Becton, Dickinson and Co the business predictability rank of 4-star.
For the last quarter Becton, Dickinson and Co reported a revenue of $4.4 billion, compared with the revenue of $3.2 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $16 billion, an increase of 32.2% from last year. For the last five years Becton, Dickinson and Co had an average revenue growth rate of 14.4% a year.
The reported diluted earnings per share was 60 cents for the year, a decline of 87% from the previous year. Over the last five years Becton, Dickinson and Co had an average EPS decline of 29.8% a year. The Becton, Dickinson and Co had a decent operating margin of 14.02%, compared with the operating margin of 15.16% a year before. The 10-year historical median operating margin of Becton, Dickinson and Co is 19.61%. The profitability rank of the company is 8 (out of 10).
At the current stock price of $242.04, Becton, Dickinson and Co is traded at 50.8% premium to its historical median P/S valuation band of $160.54. The P/S ratio of the stock is 4.15, while the historical median P/S ratio is 2.75. The intrinsic value of the stock is $4.71 a share, according to GuruFocus DCF Calculator. The stock gained 9.42% during the past 12 months.
CEO Recent Trades:
- Chairman, CEO and President Vincent A Forlenza sold 13,498 shares of BDX stock on 11/14/2018 at the average price of $235.78. The price of the stock has increased by 2.66% since.
- Chairman, CEO and President Vincent A Forlenza sold 16,866 shares of BDX stock on 11/13/2018 at the average price of $237.61. The price of the stock has increased by 1.86% since.
Directors and Officers Recent Trades:
- Executive Vice President Thomas E Polen Jr sold 5,243 shares of BDX stock on 11/19/2018 at the average price of $243.86. The price of the stock has decreased by 0.75% since.
- SVP Corp Fin Chief Acct Office Charles R Bodner sold 2,080 shares of BDX stock on 11/16/2018 at the average price of $245.83. The price of the stock has decreased by 1.54% since.
- EVP and Pres, Life Sciences Ribo Alberto Mas sold 4,530 shares of BDX stock on 11/14/2018 at the average price of $237.01. The price of the stock has increased by 2.12% since.
- Executive Vice President James C Lim sold 5,189 shares of BDX stock on 11/08/2018 at the average price of $242.36. The price of the stock has decreased by 0.13% since.
- Director Timothy M Ring sold 42,000 shares of BDX stock on 11/07/2018 at the average price of $237.07. The price of the stock has increased by 2.1% since.
For the complete 20-year historical financial data of BDX, click here.
